Skip to content

Intravascular blood volume calculated fluid therapy versus standard fluid therapy in acute pancreatitis

Intravascular fluid guided therapy versus standard fluid therapy in predicted severe acute pancreatitis: A randomized controlled studyâ?? - INFUSION In-INtravascular F- fluid U- gUided S- verSus I-predIcted O- randOmized N-coNtrolled

Status
Recruiting
Phases
Unknown
Study type
Interventional
Source
CTRI
Registry ID
CTRI/2017/12/010868
Enrollment
60
Registered
2017-12-13
Start date
Unknown
Completion date
Unknown
Last updated
2021-11-24

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Health Condition 1: K85- Acute pancreatitis Health Condition 2: null- Patients with predicted severe acute pancreatitis within 3 days of onset of illness

Interventions

Intervention1: Intravascular plasma volume guided fluid therapy group: Intravascular fluid will be infused based on calculated fluid deficit. We will calculate the fluid requirement plus maintenance f

Sponsors

All India Institute of Medical Sciences
Lead Sponsor

Eligibility

Inclusion criteria

Inclusion criteria: 1. All consecutive patients with predicted severe acute pancreatitis diagnosed as per revised Atlanta criteria will be included in the study. 2. Hospitalisation within 72 hours of onset of acute pancreatitis

Exclusion criteria

Exclusion criteria: 1. Age 60 years 2. Patients with Grade 3 / Grade 4 organ failure (as defined by modified marshall classification at enrolment). 3. Patients with underlying co-morbid cardiac, renal, hepatic disease or malignancy. 4. Patients admitted after 72 hours of onset of acute pancreatitis. 5. Pregnancy 6. Refusal to provide consent to participate in the study

Design outcomes

Primary

MeasureTime frame
Composite outcome meeting (2 out of the 4 ) adequate perfusion goals : SBP more than 100 mm Hg or 40 mm rise from baseline Pulse less than 100 beats per min Urine output more than 0.5 ml per kg per hr Lactate to normal values within 24 hours of resuscitation. Co-primary outcome will be measured by improvement in SIRS. Secondary outcome will be measured by improvement of organ failure at 72 hours and after 7 days of onset of AP and the difference in the adverse events between the groups Timepoint: from illness onset till 72 hours and 7 days

Secondary

MeasureTime frame
Secondary outcome will be measured by improvement of organ failure at 72 hours and after 7 days of onset of AP and the difference in the adverse events between the groupsTimepoint: From illness onset till 72 hours and 7 days

Countries

India

Contacts

Public ContactDr Rahul sethia

Aiims

rahulsethia018@gmail.com9818962640

Outcome results

None listed

Source: CTRI (via WHO ICTRP) · Data processed: Feb 4, 2026